The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
November 5th 2024
Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, including the latest diagnosis and treatment protocol advancements, at Advances in Pulmonary Medicine 2024.
Nivolumab Fails to Benefit Esophageal Cancer Treatment in EA2174 Trial: Dr Jennifer Eads
June 4th 2024This new analysis of nivolumab presented at ASCO 2024 shows the immune checkpoint inhibitor did not convery benefit when added to a regimen of neoadjuvant carboplatin, paclitaxel, and radiation.
Watch
TB Vaccine Shows Protection Against COVID-19 in People With T1D
June 3rd 2024In the course of investigating the use of Bacillus Calmette-Guérin for high-risk individuals who have type 1 diabetes (T1D), researchers hoped—and found—that BCG could substantially reduce the chance of those with T1D contracting COVID-19; BCG has historically been used to prevent tuberculosis (TB).
Read More
Proof-of-Concept Study Highlights Potential of Gene-Based Therapy for Timothy Disease
June 2nd 2024The proof-of-concept study showed that antisense oligonucleotides developed by the researchers successfully restored cellular development and brain cell function in patients with the disease characterized by multiorgan dysfunction.
Read More
Dr Surya Bhatt Highlights NOTUS Trial Findings, Promising Dupilumab Results
June 1st 2024Surya Bhatt, MD, MSPH, of the University of Alabama at Birmingham, discussed the challenges of diagnosing chronic obstructive pulmonary disease (COPD) with type 2 inflammation, as well as the promising efficacy of dupilumab in treating this condition.
Watch
Keratinocyte Cancers Most Commonly Located on the Head and Neck, US Study Finds
May 31st 2024A large Medicare cohort study found that the most common locations of procedurally treated keratinocyte cancers in the US were the head and/or neck for both squamous cell carcinomas and basal cell carcinomas.
Read More
There has been a lack of visible progress from RECOVER, the $1.6 billion initiative launched by the National Institutes of Health to research long COVID; the CDC has detected a third human case of bird flu linked to sick dairy cows; small businesses and their workers are struggling to receive weight-loss drug insurance coverage.
Read More
Management of Procalcitonin Test Overuse in an Emergency Department Through a Computer Algorithm
Procalcitonin test demand from the emergency department is growing, necessitating the implementation of strategies to address overuse. Successful interventions must be based on information technology.
Read More
Interventional Analytics in Skilled Nursing Facilities Associated With Reduced Readmissions
A retrospective analysis of 30-day risk-adjusted readmission rates among skilled nursing facilities (SNFs) between 2017 and 2022 compared those that had implemented an interventional analytics platform and other SNFs.
Read More
Modeling the Economic Value of Cardiometabolic Virtual-First Care Programs
Using a microsimulation approach, this study modeled the potential multiyear health and economic benefits of participating in cardiometabolic virtual-first care programs.
Read More
This study quantified the trends over time in utilization of, spending on, and access to CT fractional flow reserve, the first artificial intelligence (AI)–enabled clinical software reimbursed by Medicare.
Read More
What We’re Reading: Clinical Trial Diversity; Nicotine-Like Vape Chemicals; Weight-Loss Drug Tracker
May 30th 2024Despite diversity enrollment goals, clinical trials funded by the National Institutes of Health (NIH) often enroll fewer patients among underrepresented racial groups; nicotine alternatives used in vapes may be more potent and addictive than nicotine itself; telehealth company Ro built a drug supply tracker to help patients find available doses of GLP-1 drugs.
Read More
Identifying the Most Impactful Disease Areas and Patient Populations for PDTs
May 29th 2024Diana Brixner, PhD, highlights the potential for prescription digital therapeutics (PDTs) to have impact in areas such as facilitating behavioral change for mental health conditions and strengthening adherence for complex disease states with intricate drug regimens.
Watch